Use: Labeled indications
- Dicyclomine hydrochloride tablets are indicated for the treatment of patients with functional bowel/irritable bowel syndrome.
Full indications and usage US FDA label
1 INDICATIONS AND USAGE Dicyclomine hydrochloride tablets are indicated for the treatment of patients with functional bowel/irritable bowel syndrome. Dicyclomine hydrochloride is an antispasmodic and anticholinergic (antimuscarinic) agent indicated for the treatment of functional bowel/irritable bowel syndrome (1)
Contraindications
4 CONTRAINDICATIONS Dicyclomine hydrochloride is contraindicated in infants less than 6 months of age [see Use in Specific Populations (8.4)], nursing mothers [see Use in Specific Populations (8.3)], and in patients with: unstable cardiovascular status in acute hemorrhage myasthenia gravis [see Warnings and Precautions (5.4)] glaucoma [see Adverse Reactions (6.3) and Drug Interactions (7.1)] obstructive uropathy [see Warnings and Precautions (5.8)] obstructive disease of the gastrointestinal tract [see Warnings and Precautions (5.5)] severe ulcerative colitis [see Warnings and Precautions (5.7)] reflux esophagitis Infants less than 6 months of age (4) Glaucoma (4) Nursing mothers (4) Obstructive uropathy (4) Unstable cardiovascular status in the acute hemorrhage (4) Obstructive disease of gastrointestinal tract (4) Myasthenia gravis (4) Severe ulcerative colitis (4) Reflux esophagitis (4)
US FDA labelDosing: Adult
Dosage and administration (US label) US FDA label
2 DOSAGE AND ADMINISTRATION Dosage must be adjusted to individual patient needs. Dosage for dicyclomine hydrochloride tablets must be adjusted to individual patient needs (2). If a dose is missed, patients should continue the normal dosing schedule. (2). Oral in adults (2.1): Starting dose: 20 mg four times a day. After a week treatment with the starting dose, the dose may be escalated to 40 mg four times a day, unless side effects limit dosage escalation Discontinue dicyclomine hydrochloride tablets if efficacy not achieved or side effects require doses less than 80 mg per day after two weeks of treatment 2.1 Oral Dosage and Administration in Adults The recommended initial dose is 20 mg four times a day.
After one week treatment with the initial dose, the dose may be increased to 40 mg four times a day unless side effects limit dosage escalation. If efficacy is not achieved within 2 weeks or side effects require doses below 80 mg per day, the drug should be discontinued. Documented safety data are not available for doses above 80 mg daily for periods longer than 2 weeks.
Dosing: Altered kidney function
8.6 Renal Impairment Effects of renal impairment on PK, safety and efficacy of dicyclomine hydrochloride have not been studied. Dicyclomine hydrochloride drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Dicyclomine hydrochloride tablets should be administered with caution in patients with renal impairment.
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosing: Hepatic impairment
8.7 Hepatic Impairment Effects of renal impairment on PK, safety and efficacy of dicyclomine hydrochloride has not been studied. Dicyclomine hydrochloride tablets should be administered with caution in patients with hepatic impairment.
US FDA labelDosing: Pediatric
Pediatric use (US label) US FDA label
8.4 Pediatric Use Safety and effectiveness in pediatric patients have not been established. Dicyclomine hydrochloride is contraindicated in infants less than 6 months of age [see Contraindications (4)]. There are published cases reporting that the administration of dicyclomine hydrochloride to infants has been followed by serious respiratory symptoms (dyspnea, shortness of breath, breathlessness, respiratory collapse, apnea and asphyxia), seizures, syncope, pulse rate fluctuations, muscular hypotonia, and coma, and death, however; no causal relationship has been established.
Dosing: Older adult
Geriatric use (US label) US FDA label
8.5 Geriatric Use Clinical studies of dicyclomine hydrochloride tablets did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients.
In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range in adults, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.
Administration
2.1 Oral Dosage and Administration in Adults The recommended initial dose is 20 mg four times a day. After one week treatment with the initial dose, the dose may be increased to 40 mg four times a day unless side effects limit dosage escalation. If efficacy is not achieved within 2 weeks or side effects require doses below 80 mg per day, the drug should be discontinued. Documented safety data are not available for doses above 80 mg daily for periods longer than 2 weeks.
US FDA labelDosage forms
Philippines
- Syrup: 5 mg/mL, 10 mg per 5 mL, 10 mg/5 mL
- Tablet: 10 mg
Registered products in the Philippines
35 products registered with the Food and Drug Administration (FDA) Philippines list Dicycloverine as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products35
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
ClomedDicycloverine Hydrochloride | 10mg TabletAlu/Clear PVC Blister Pack x 20's (Box of 100's) | Rx | Drugmaker's Laboratories, Inc.Philippines | — | DRP-5823 | Jul 29, 2028 | |
CloverineDicycloverine Hydrochloride | 10 mg TabletAlu/Clear PVC Blister Pack x 20's (Box of 100's) | Rx | Azarias Pharmaceutical Laboratories Inc.Philippines | ST. RAPHAEL ARCHANGEL PHARMACEUTICAL PRODUCT DISTRIBUTION | DRP-4522-03 | Jul 12, 2028 | |
CycliumDicycloverine Hydrochloride | 10 mg/5 mL SyrupAmber Glass Bottle x 60 mL (Box of 1's) | Rx | New Myrex Laboratories, Inc.Philippines | — | DR-XY10621 | Dec 28, 2031 | |
DiacielDicycloverine Hydrochloride | 10 mg / 5 mL Syrup (Strawberry Flavor)Amber Glass Bottle x 60 mL (Box of 1's) | Rx | Diamond Laboratories, Inc.Philippines | Rilem Pharma Corp. | DRP-7238 | Feb 10, 2032 | |
DiacielDicycloverine Hydrochloride | 10 mg TabletAlu/Clear PVC Blister Pack x 20's (Box of 100's) | Rx | Diamond Laboratories, IncPhilippines | Rilem Pharma Corp. | DRP-7535 | Aug 4, 2031 | |
Dicol-SDicycloverine Hydrochloride | 10 mg/5 mL Syrup60 mL Amber Glass Bottle (Box of 1's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Westfield Pharmaceuticals, Inc. | DRP-11823 | Jun 20, 2028 | |
DicyclogenDicycloverine Hydrochloride | 10 mg TabletAlu/Clear PVC Blister Pack x 20's (Box of 100's) | Rx | Azarias Pharmaceutical Laboratories Inc.Philippines | EBA GENERISCH TRADING INC. | DRP-4522-01 | Jul 12, 2028 | |
DicyclogenDicycloverine hydrochloride | 5 mg/mL Syrup (Oral Drops)Amber Glass Bottle x 15 mL (Box of 1's) | Rx | Azarias Pharmaceutical Laboratories Inc.Philippines | Eba Generische Trading Inc. | DRP-5274-01 | Jul 9, 2027 | |
DicymedDicycloverine (as Hydrochloride) | 10 mg TabletAlu/PVC Blister Pack x 20's Box of 100's | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Medhaus Pharma Inc. | DR-XY18698 | Jun 24, 2027 | |
DicymedDicycloverine Hydrochloride | 10 mg/5 mL SyrupAmber Glass Bottle x 60 mL (Box of 1's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Medhaus Pharma, Incorporated | DR-XY18411 | Apr 22, 2027 | |
DicyrineDicycloverine Hydrochloride | 10 mg TabletAlu/Clear PVC Blister pack x 20's (Box of 100's) | Rx | Drugmaker's Laboratories, Inc.Philippines | Drugmaker's Laboratories, Inc. | DRP-5823-01 | Jul 29, 2028 | |
DilominDicycloverine Hydrochloride | 10 mg TabletAlu/PVC Blister Pack x 10's and 20's (Box of 100's) | Rx | AM-EUROPHARMA CORPORATIONPhilippines | RILEM PHARMA CORP | DRP-2968 | Sep 5, 2029 | |
DisaphverineDicycloverine Hydrochloride | 10mg/5mL Syrup60 mL and 120 mL PET Round Amber Bottle [Box of 1's) | Rx | Enicar Pharmaceuticals Pvt. Ltd.India | Nelpa Lifesciences, Inc.Trader: Sapphire Lifesciences Pvt. Ltd. | DRP-13251 | Jan 17, 2028 | |
GasaideDicycloverine Hydrochloride | 10 mg TabletAlu/Clear PVC Blister Pack x 20's (Box of 60's and 100's); Alu/Clear PVC Blister Pack x 40's (Box of 40's and 120's) | Rx | Azarias Pharmaceutical Laboratories Inc.Philippines | — | DRP-4522 | Jul 12, 2028 | |
GasaideDicycloverine (as Hydrochloride) | 10 mg/5 mL SyrupBoston Round Amber Glass Bottle x 60 mL (Box of 1's) | Rx | Azarias Pharmaceutical Laboratories, Inc.Bulacan | — | DRP-3246 | Sep 22, 2031 | |
GasaideDicycloverine Hydrochloride | 5 mg/mL Syrup (Oral Drops)Amber Glass Bottle x 15 mL (Box of 1's) | Rx | Azarias Pharmaceutical Laboratories, Inc.Philippines | — | DRP-5274 | Jul 9, 2027 | |
MotimovDicycloverine Hydrochloride | 10mg/5mL Syrup | Rx | AZARIAS PHARMACEUTICAL LABORATORIES INC. | — | DRP-3499 | Jan 13, 2027 | |
MotimovDicycloverine Hydrochloride | 5 mg/mL Syrup (Oral Drops)Amber Glass Bottle x 15 mL with Dropper (Box of 1's) | Rx | Azarias Pharmaceutical Laboratories Inc.Bulacan | — | DRP-3282 | Jun 14, 2031 | |
MyrentylDicycloverine hydrochloride | 10 mg/5 mL SyrupAmber Glass Bottle x 60 mL with 20 mm white pilfer proof aluminum metal cap (Box of 1's) | Rx | New Myrex Laboratories, Inc.Philippines | — | DRP-4425 | Jul 22, 2028 | |
NoneDicycloverine Hydrochloride | 10 mg TabletAlu/PVC Blister Pack x 10s and 20s (Box of 100s) | Rx | Am-Europharma CorporationPhilippines | RITEMED PHILS., INC. | DRP-2968-01 | Sep 5, 2029 | |
NoneDicycloverine hydrochloride | 10 mg/5 mL SyrupBoston Round Amber Glass Bottle x 60 mL (Box of 1's) | Rx | AM-Europharma CorporationPhilippines | RiteMED Phils., Inc. | DR-XY10009-B | Jul 5, 2031 | |
NoneDicycloverine Hydrochloride | 10 mg/5 mL SyrupAmber glass bottle x 60 mL (Box of 1's) | Rx | Drugmaker's Laboratories Inc.Philippines | TGP Pharma Inc | DRP-5777-01 | Apr 5, 2031 | |
NoneDicycloverine Hydrochloride | 10mg TabletAlu/Clear PVC Blister pack x 20's (Box of 100's) | Rx | Drugmaker's Laboratories, Inc.Philippines | TGP Pharma Inc. | DRP-5823-02 | Jul 29, 2028 | |
RelestalDicycloverine hydrochloride | 10 mg/5 mL SyrupAmber Glass Bottle x 60 mL Box of 1's | Rx | Amherst Laboratories, Inc.Philippines | Trader: Pediatrica, Inc. | DRP-11901 | Nov 20, 2030 | |
RelestalDicycloverine hydrochloride | 5 mg/mL Syrup (Oral Drops)Boston Round Amber Glass Bottle with Medicine Dropper x 15 mL (Box of 1's) | Rx | Amherst Laboratories, Inc.Philippines | Trader: Pediatrica, Inc. | DRP-11900 | Nov 20, 2030 | |
ReliefasDicycloverine Hydrochloride | 5 mg / mL Syrup (Oral Drops)Amber Glass Bottle x 15 mL (Box of 1's) | Rx | Azarias Pharmaceutical Laboratories Inc.Philippines | Curecare Pharmaceutical Products Distribution | DRP-5274-02 | Jul 9, 2027 | |
SpasdonDicycloverine Hydrochloride | 5 mg/mL Syrup (Oral Drops)Amber Glass Bottle with Dropper x 15 mL; Amber Glass Bottle with Dropper x 15 mL (as Physician Sample) | Rx | AD-Drugstel Pharmaceutical Laboratories, Inc.Philippines | — | DRP-4850 | Sep 26, 2028 | |
SpasmodrylDicycloverine (as hydrochloride) | 10 mg per 5 mL SyrupAmber Glass Bottle x 10 mL (as physician's sample) and 60 mL Box of 1's | Rx | Scheele Laboratories Phils, Inc.Philippines | Zeutica, Inc. | DRP-3670-01 | Mar 15, 2027 | |
SpasmolineDicycloverine (as Hydrochloride) | 10 mg per 5 mL SyrupAmber Glass Bottle x 10 mL (as physician's sample) and 60 mL [Box of 1's] | Rx | Scheele Laboratories Phils., Inc.Philippines | — | DRP-3670 | Mar 15, 2027 | |
SpasmoverinDicycloverine Hydrochloride | 10 mg/5 mL SyrupAmber glass bottle x 60 mL Box of 1's | Rx | Drugmaker's Laboratories Inc.Philippines | — | DRP-5777 | May 30, 2030 | |
UnbrandedDicycloverine Hydrochloride | 10 mg TabletAluminum Foil Strip x 10's Box of 100's | Rx | Hizon Laboratories, Inc.Philippines | — | DR-XY43480 | Jun 27, 2029 | |
YCLOVIRDicycloverine Hydrochloride | 10 mg TabletAlu/Clear PVC Blister Pack x 20's (Box of 100's) | Rx | Azarias Pharmaceutical Laboratories Inc.Philippines | KONZEPT CONVENIENCE AND DRUG STORE CORP. | DRP-4522-04 | Jul 12, 2028 | |
ZyclodexDicycloverine (as Hydrochloride) | 10 mg TabletAlu/PVC Blister Pack x 20's (Box of 100's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Eadriex Pharmaceuticals, Phils., Inc. | DR-XY22291 | Dec 2, 2027 | |
ZyclodexDicycloverine Hydrochloride | 10 mg/5 mL SyrupAmber Glass Bottle x 60 mL (Box of 1's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Eadriex Pharmaceuticals, Phils., Inc. | DR-XY19211 | Nov 20, 2027 | |
(no brand name)Dicycloverine Hydrochloride | 10 mg TabletAlu/Clear PVC-PVC Blister Pack x 20 (Box of 100's) | Rx | Lloyd Laboratories, Inc.Philippines | — | DRP-10880 | Dec 10, 2026 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
United States (label)
Dosage forms and strengths (US label) US FDA label
3 DOSAGE FORMS AND STRENGTHS Dicyclomine hydrochloride tablets, USP 20 mg: Light blue to blue, speckled, round, unscored, flat-faced, beveled-edge tablets, debossed ‘˄’ and ‘A2’ on one side and plain on the other side. Dicyclomine hydrochloride tablets, USP 40 mg: Light blue to blue, speckled, oval shaped, concave tablet with scoreline on both sides, debossed on one side with ‘^’ and ‘H6’ on either side of scoreline. Dicyclomine hydrochloride tablets 20 mg (3) Dicyclomine hydrochloride tablets 40 mg (3)
Warnings/Precautions
- Cardiovascular conditions: worsening of conditions (5.2)
- Peripheral and central nervous system: heat prostration can occur with drug use (fever and heat stroke due to decreased sweating); drug should be discontinued and supportive measures instituted (5.3)
- Psychosis and delirium have been reported in patients sensitive to anticholinergic drugs (such as elderly patients and/or in patients with mental illness): signs and symptoms resolve within 12 to 24 hours after discontinuation of dicyclomine hydrochloride tablets (5.3)
- Myasthenia Gravis: overdose may lead to muscular weakness and paralysis. Dicyclomine hydrochloride tablets should be given to patients with myasthenia gravis only to reduce adverse muscarinic effects of an anticholinesterase (5.4)
- Incomplete intestinal obstruction: diarrhea may be an early symptom especially in patients with ileostomy or colostomy. Treatment with dicyclomine hydrochloride tablets would be inappropriate and possibly fatal (5.5)
- Salmonella dysenteric patients: due to risk of toxic megacolon (5.6)
- Ulcerative colitis: Dicyclomine hydrochloride tablets should be used with caution in these patients; large doses may suppress intestinal motility or aggravate the serious complications of toxic megacolon (5.7)
- Prostatic hypertrophy: Dicyclomine hydrochloride tablets should be used with caution in these patients; may lead to urinary …
5.2 Cardiovascular Conditions
5.2 Cardiovascular Conditions Dicyclomine hydrochloride needs to be used with caution in conditions characterized by tachyarrhythmia such as thyrotoxicosis, congestive heart failure and in cardiac surgery, where they may further accelerate the heart rate. Investigate any tachycardia before administration of dicyclomine hydrochloride.
Care is required in patients with coronary heart disease, as ischemia and infarction may be worsened, and in patients with hypertension [see Adverse Reactions (6.3)].
5.3 Peripheral and Central Nervous System
5.3 Peripheral and Central Nervous System The peripheral effects of dicyclomine hydrochloride are a consequence of their inhibitory effect on muscarinic receptors of the autonomic nervous system. They include dryness of the mouth with difficulty in swallowing and talking, thirst, reduced bronchial secretions, dilatation of the pupils (mydriasis) with loss of accommodation (cycloplegia) and photophobia, flushing and dryness of the skin, transient bradycardia followed by tachycardia, with palpitations and arrhythmias, and difficulty in micturition, as well as reduction in the tone and motility of the gastrointestinal tract leading to constipation [see Adverse Reactions (6)].
In the presence of high environmental temperature heat prostration can occur with drug use (fever and heat stroke due to decreased sweating). It should also be used cautiously in patients with fever. If symptoms occur, the drug should be discontinued and supportive measures instituted. Because of the inhibitory effect on muscarinic receptors within the autonomic nervous system, caution should be taken in patients with autonomic neuropathy.
Central nervous system (CNS) signs and symptoms include confusional state, disorientation, amnesia, hallucinations, dysarthria, ataxia, coma, euphoria, fatigue, insomnia, agitation and mannerisms, and inappropriate affect. Psychosis and delirium have been reported in sensitive individuals (such as elderly patients and/or in patients with mental illness) given anticholinergic drugs.
These CNS signs and symptoms usually resolve within 12 to 24 hours after discontinuation of the drug. Dicyclomine hydrochloride may produce drowsiness, dizziness or blurred vision. The patient should be warned not to engage in activities requiring mental alertness, such as operating a motor vehicle or other machinery or performing hazardous work while taking dicyclomine hydrochloride.
5.4 Myasthenia Gravis
5.4 Myasthenia Gravis With overdosage, a curare-like action may occur (i.e., neuromuscular blockade leading to muscular weakness and possible paralysis). It should not be given to patients with myasthenia gravis except to reduce adverse muscarinic effects of an anticholinesterase [see Contraindications (4)].
5.5 Intestinal Obstruction
5.5 Intestinal Obstruction Diarrhea may be an early symptom of incomplete intestinal obstruction, especially in patients with ileostomy or colostomy. In this instance, treatment with this drug would be inappropriate and possibly harmful [see Contraindications (4)]. Rarely development of Ogilvie’s syndrome (colonic pseudo-obstruction) has been reported.
Ogilvie’s syndrome is a clinical disorder with signs, symptoms, and radiographic appearance of an acute large bowel obstruction but with no evidence of distal colonic obstruction.
5.6 Toxic Dilatation of Intestinemegacolon
5.6 Toxic Dilatation of Intestinemegacolon Toxic dilatation of intestine and intestinal perforation is possible when anticholinergic agents are administered in patients with Salmonella dysentery.
5.7 Ulcerative Colitis
5.7 Ulcerative Colitis Caution should be taken in patients with ulcerative colitis. Large doses may suppress intestinal motility to the point of producing a paralytic ileus and the use of this drug may precipitate or aggravate the serious complication of toxic megacolon [see Adverse Reactions (6.3)]. Dicyclomine hydrochloride tablets are contraindicated in patients with severe ulcerative colitis [see Contraindications (4)].
5.8 Prostatic Hypertrophy
5.8 Prostatic Hypertrophy Dicyclomine hydrochloride should be used with caution in patients with known or suspected prostatic enlargement, in whom prostatic enlargement may lead to urinary retention [see Adverse Reactions (6.3)].
5.9 Hepatic and Renal Disease
5.9 Hepatic and Renal Disease Dicyclomine hydrochloride should be used with caution in patients with known hepatic and renal impairment.
5.10 Geriatric Population
5.10 Geriatric Population Dicyclomine hydrochloride should be used with caution in elderly who may be more susceptible to its adverse effects.
Drug interactions
Antiglaucoma agents: anticholinergics antagonize antiglaucoma agents and may increase intraoccular pressure (7) Anticholinergic agents: may affect the gastrointestinal absorption of various drugs; may also increase certain actions or side effects of other anticholinergic drugs (7) Antacids: interfere with the absorption of anticholinergic agents (7)
7.1 Antiglaucoma Agents
7.1 Antiglaucoma Agents Anticholinergics antagonize the effects of antiglaucoma agents. Anticholinergic drugs in the presence of increased intraocular pressure may be hazardous when taken concurrently with agents such as corticosteroids. Use of dicyclomine hydrochloride tablets in patients with glaucoma is not recommended [see Contraindications (4)].
7.2 Other Drugs with Anticholinergic Activity
7.2 Other Drugs with Anticholinergic Activity The following agents may increase certain actions or side effects of anticholinergic drugs including dicyclomine hydrochloride: amantadine, antiarrhythmic agents of Class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.
7.3 Other Gastrointestinal Motility Drugs
7.3 Other Gastrointestinal Motility Drugs Interaction with other gastrointestinal motility drugs may antagonize the effects of drugs that alter gastrointestinal motility, such as metoclopramide.
7.4 Effect of Antacids
7.4 Effect of Antacids Because antacids may interfere with the absorption of anticholinergic agents including dicyclomine hydrochloride, simultaneous use of these drugs should be avoided.
7.5 Effect on Absorption of Other Drugs
7.5 Effect on Absorption of Other Drugs Anticholinergic agents may affect gastrointestinal absorption of various drugs by affecting on gastrointestinal motility, such as slowly dissolving dosage forms of digoxin; increased serum digoxin concentration may result.
7.6 Effect on Gastric Acid Secretion
7.6 Effect on Gastric Acid Secretion The inhibiting effects of anticholinergic drugs on gastric hydrochloric acid secretion are antagonized by agents used to treat achlorhydria and those used to test gastric secretion.
Adverse reactions
The pattern of adverse effects seen with dicylomine is mostly related to its pharmacological actions at muscarinic receptors [see Clinical Pharmacology (12)]. They are a consequence of the inhibitory effect on muscarinic receptors within the autonomic nervous system. These effects are dose-related and are usually reversible when treatment is discontinued.
The most serious adverse reactions reported with dicyclomine hydrochloride include cardiovascular and central nervous system symptoms [see Warnings and Precautions (5.2, 5.3)]. The most serious adverse reactions include cardiovascular and central nervous system symptoms. The most common adverse reactions (> 5% of patients) are dizziness, dry mouth, vision blurred, nausea, somnolence, asthenia and nervousness (6) To report SUSPECTED ADVERSE REACTIONS, contact Advagen Pharma Ltd, at 866-488-0312 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Trials Experience
6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The data described below reflect exposure in controlled clinical trials involving over 100 patients treated for functional bowel/irritable bowel syndrome with dicyclomine hydrochloride at initial doses of 160 mg daily (40 mg four times a day) In these trials most of the side effects were typically anticholinergic in nature and were reported by 61% of the patients.
Table 1 presents adverse reactions (MedDRA 13.0 preferred terms) by decreasing order of frequency in a side-by-side comparison with placebo. Table 1: Adverse reactions experienced in controlled clinical trials with decreasing order of frequency MedDRA Preferred Term Dicyclomine Hydrochloride (40 mg four times a day) % Placebo % Dry Mouth 33 5 Dizziness 40 5 Vision blurred 27 2 Nausea 14 6 Somnolence 9 1 Asthenia 7 1 Nervousness 6 2 Nine percent (9%) of patients were discontinued from dicyclomine hydrochloride because of one or more of these side effects (compared with 2% in the placebo group).
In 41% of the patients with side effects, side effects disappeared or were tolerated at the 160 mg daily dose without reduction. A dose reduction from 160 mg daily to an average daily dose of 90 mg was required in 46% of the patients with side effects who then continued to experience a favorable clinical response; their side effects either disappeared or were tolerated.
6.2 Postmarketing Experience
6.2 Postmarketing Experience The following adverse reactions, presented by system organ class in alphabetical order, have been identified during post approval use of dicyclomine hydrochloride. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Cardiac disorders: palpitations, tachyarrhythmias Eye disorders: cycloplegia, mydriasis, vision blurred Gastrointestinal disorders: abdominal distension, abdominal pain, constipation, dry mouth, dyspepsia, nausea, vomiting General disorders and administration site conditions: fatigue, malaise Immune System Disorders: drug hypersensitivity including face edema, angioedema, anaphylactic shock Nervous system disorders: dizziness, headache, somnolence, syncope Psychiatric disorders: As with the other anti-cholinergic drugs, cases of delirium or symptoms of delirium such as amnesia (or transient global amnesia), agitation, confusional state, delusion, disorientation, hallucination (including visual hallucination) as well as mania, mood altered and pseudodementia, have been reported with the use of dicyclomine. Nervousness and insomnia have also been reported.
Reproductive system and breast disorders: suppressed lactation Respiratory, thoracic and mediastinal disorders: dyspnoea, nasal congestion Skin and subcutaneous tissue disorder: dermatitis allergic, erythema, rash
6.3 Adverse Reactions Reported with Similar Drugs with Anticholinergic/Antispasmodic Action…
6.3 Adverse Reactions Reported with Similar Drugs with Anticholinergic/Antispasmodic Action Gastrointestinal: anorexia Central Nervous System: tingling, numbness, dyskinesia, speech disturbance, insomnia Peripheral Nervous System: With overdosage, a curare-like action may occur (i.e., neuromuscular blockade leading to muscular weakness and possible paralysis) Ophthalmologic: diplopia, increased ocular tension Dermatologic/Allergic: urticaria, itching, and other dermal manifestations Genitourinary: urinary hesitancy, urinary retention in patients with prostatic hypertrophy Cardiovascular: hypertension Respiratory: apnea Other: decreased sweating, sneezing, throat congestion, impotence.
Adverse reaction frequency tables (US label) US FDA label
| MedDRA Preferred Term | Dicyclomine Hydrochloride (40 mg four times a day) % | Placebo % |
| Dry Mouth | 33 | 5 |
| Dizziness | 40 | 5 |
| Vision blurred | 27 | 2 |
| Nausea | 14 | 6 |
| Somnolence | 9 | 1 |
| Asthenia | 7 | 1 |
| Nervousness | 6 | 2 |
Pregnancy considerations
Pregnancy (US label) US FDA label
8.1 Pregnancy Pregnancy Category B Adequate and well-controlled studies have not been conducted with dicyclomine hydrochloride in pregnant women at the recommended doses of 80 to 160 mg/day. However, epidemiologic studies did not show an increased risk of structural malformations among babies born to women who took products containing dicyclomine hydrochloride at doses up to 40 mg/day during the first trimester of pregnancy.
Reproduction studies have been performed in rats and rabbits at doses up to 33 times the maximum recommended human dose based on 160 mg/day (3 mg/kg) and have revealed no evidence of harm to the fetus due to dicyclomine. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.
Breastfeeding considerations
Lactation (US label) US FDA label
8.3 Nursing Mothers Dicyclomine hydrochloride is contraindicated in women who are breastfeeding. Dicyclomine hydrochloride is excreted in human milk. Because of the potential for serious adverse reactions in breast-fed infants from dicyclomine hydrochloride tablets, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother [see Use in Specific Populations (8.4)].
Mechanism of action
12.1 Mechanism of Action Dicyclomine relieves smooth muscle spasm of the gastrointestinal tract. Animal studies indicate that this action is achieved via a dual mechanism: a specific anticholinergic effect (antimuscarinic) at the acetylcholine-receptor sites with approximately 1/8 the milligram potency of atropine (in vitro, guinea pig ileum); and a direct effect upon smooth muscle (musculotropic) as evidenced by dicyclomine’s antagonism of bradykinin- and histamine-induced spasms of the isolated guinea pig ileum.
Atropine did not affect responses to these two agonists. In vivo studies in cats and dogs showed dicyclomine to be equally potent against acetylcholine (ACh)- or barium chloride (BaCl2)-induced intestinal spasm while atropine was at least 200 times more potent against effects of ACh than BaCl2. Tests for mydriatic effects in mice showed that dicyclomine was approximately 1/500 as potent as atropine; antisialagogue tests in rabbits showed dicyclomine to be 1/300 as potent as atropine.
US FDA labelPharmacodynamics
Pharmacodynamics (US label) US FDA label
12.2 Pharmacodynamics Dicyclomine hydrochloride can inhibit the secretion of saliva and sweat, decrease gastrointestinal secretions and motility, cause drowsiness, dilate the pupils, increase heart rate, and depress motor function
Pharmacokinetics
Elimination The metabolism of dicyclomine was not studied The principal route of excretion is via the urine (79.5% of the dose).
Excretion also occurs in the feces, but to a lesser extent (8.4%).
Mean half-life of plasma elimination in one study was determined to be approximately 1.8 hours when plasma concentrations were measured for 9 hours after a single dose.
In subsequent studies, plasma concentrations were followed for up to 24 hours after a single dose, showing a secondary phase of elimination with a somewhat longer half-life.
Pharmacokinetics (US label) US FDA label
12.3 Pharmacokinetics Absorption and Distribution In man, dicyclomine is rapidly absorbed after oral administration, reaching peak values within 60-90 minutes. Mean volume of distribution for a 20 mg oral dose is approximately 3.65 L/kg suggesting extensive distribution in tissues. Elimination The metabolism of dicyclomine was not studied The principal route of excretion is via the urine (79.5% of the dose).
Excretion also occurs in the feces, but to a lesser extent (8.4%). Mean half-life of plasma elimination in one study was determined to be approximately 1.8 hours when plasma concentrations were measured for 9 hours after a single dose. In subsequent studies, plasma concentrations were followed for up to 24 hours after a single dose, showing a secondary phase of elimination with a somewhat longer half-life.
Formulary and pricing (Philippines)
Government price references
| Preparation | Price (PHP) | Unit | Type |
|---|---|---|---|
| Dicycloverine (Dicyclomine) 10 mg Tablet | ₱0.44–₱0.65Reference ₱0.52 | per tablet | DPRI procurement range |
| Dicycloverine (Dicyclomine) 10 mg/5 mL, 60 mL Syrup | ₱12.30–₱14.00Reference ₱13.50 | per unit | DPRI procurement range |
Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)
These are government procurement and reimbursement references, not retail prices. Sources:
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf, as of September 17, 2021
Formulary and coverage
| Philippine National Formulary | Listed as Dicycloverine (Dicyclomine) (as hydrochloride) |
| PNF listing | Oral: 10 mg tablet |
| PNF listing | Oral: 10 mg/5 mL syrup, 60 mL |
| PhilHealth GAMOT | No |
Sources:
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf, as of November 2, 2022
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. Dicyclomine hydrochloride · Advagen Pharma Ltd., [US FDA-approved label, version 4, November 2, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b4331e24-58af-45fb-a25b-9eb8270f83f7
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .